info@cymabay.com
(510) 293-8800
Home
About
Overview
Management Team
Board of Directors
Careers
Clinical Trials
Pipeline
Overview
Seladelpar
Additional Programs
Expanded Access
Clinical Trials
Collaborations
News
Press Releases
Upcoming Events
Investors
Contact
Investors
Home
/
Investors
/
Press Releases
Press Releases
Overview
News / Events
Press Releases
Events
Presentations
Publications
Email Alerts
Company Information
Profile
Management Team
IR Contacts
FAQ
Financial Information
Financials
Quarterly Results
Stock Data
Quote
Charts
Historical Data
Analyst Coverage
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Corporate Governance
Board of Directors
Board Committees
Governance Docs
Email Alerts
IR Contacts
RSS News Feed
All News
By Year:
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
26
Nov
CymaBay Therapeutics to Present at the Piper Jaffray 26th Annual Healthcare Conference
12
Nov
CymaBay Reports Third Quarter 2014 Financial Results
31
Oct
CymaBay Therapeutics to Announce Third Quarter 2014 Financial Results on Wednesday, November 12, 2014
15
Oct
CymaBay Therapeutics to Participate in Two Upcoming Investor Conferences
29
Sep
CymaBay Completes Enrollment in its Phase 2b Study of Arhalofenate in Patients with Gout
28
Jul
CymaBay Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
22
Jul
CymaBay Therapeutics Announces Pricing of Public Offering of Common Stock
17
Jul
CymaBay Therapeutics Announces Proposed Offering of Common Stock
16
Jun
CymaBay Therapeutics Announces Uplisting to the NASDAQ Capital Market Under the Symbol "CBAY"
2
Jun
CymaBay Therapeutics to Present at Upcoming Conferences
1
2
Next >>
Show All
Scroll
